Blueprint Medicines (NASDAQ: BPMC)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Blueprint Medicines (NASDAQ: BPMC) through any online brokerage.
The latest price target for Blueprint Medicines (NASDAQ: BPMC) was reported by Wells Fargo on Monday, June 27, 2022. The analyst firm set a price target for 40.00 expecting BPMC to fall to within 12 months (a possible -25.18% downside). 17 analyst firms have reported ratings in the last year.
The stock price for Blueprint Medicines (NASDAQ: BPMC) is $53.46 last updated June 28, 2022, 8:00 PM UTC.
There are no upcoming dividends for Blueprint Medicines.
Blueprint Medicines’s Q2 earnings are confirmed for Thursday, July 28, 2022.
There is no upcoming split for Blueprint Medicines.
Blueprint Medicines is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.